Our History

Our History

Our History

We have a rich heritage spanning many decades, from our successful commercialisation of intellectual property to our transformation into a specialist healthcare company.

Along the way we have partnered with some of the world’s leading healthcare companies and played a part in the development of a number of significant medical innovations. Most recently, we have created a growing specialist healthcare company that is focused on meeting the needs of specialist physicians and their patients.

2016 Acquisition of Galil Medical Inc.
2015 Acquisition of PneumRx, Inc.
2014 Varithena® (polidocanol injectable foam) 1% launched in the US; BTG begins selling its own Interventional Oncology products in the EU.
2013 Acquisition of EKOS Corporation; Acquisition of TheraSphere®; Completed the sale of our brachytherapy business to Eckert & Ziegler BEBIG s.a.; Varithena® (polidocanol injectable foam) 1% approved in the US
2012 Voraxaze® (glucarpidase) approved and launched in the US; Positive results reported from US pivotal Phase III trials of Varithena® (polidocanol injectable foam); US and EU approve expanded Zytiga® (abiraterone acetate) indication for treatment of metastatic castration-resistant prostate cancer
2011 Acquisition of Biocompatibles International plc; Zytiga® approved in the US and EU
2010  BTG begins selling its own products in the US; Varithena® (polidocanol injectable foam) begins Phase III trials in the US; DigiFab® (digoxin immune fab (ovine)) receives first European regulatory approval
2009  AstraZeneca initiates global Phase IIb study of AZD9773 (CytoFab™) 
2008 Acquisition of Protherics PLC 
2006 Divestment of the majority of the physical sciences IP portfolio
2005  Strategic business review leads to focus on life sciences
2003  Nobel Prize for Medicine awarded to inventor of MRI, a technology first licensed by BTG in the 1980s
2002 US launch of DigiFab®, a treatment for the toxic effects of over dosage with the heart drug digoxin
2001  US launch of CroFab® (crotalidae polyvalent immune fab (ovine)), the first new rattlesnake antivenom on the US market in 50 years; US approval of Campath® (alemtuzumab) and EU approval of MabCampath® (alemtuzumab) for chronic lymphocytic leukaemia
1997  BeneFIX® (coagulation factor IX (recombinant)) treatment for haemophilia B launched in the US
1996 Following settlement with Johnson & Johnson for the Two-Part Hip Cup patents, BTG licensed them to all major orthopaedic companies.
1995  BTG plc is listed on the London Stock Exchange (LSE:BGC (now LSE:BTG))
1992 BTG is privatised
1981 BTG is formed from the merger of the National Research & Development Council and the National Enterprise Board
1970s  Development and launch of: cholesterol assay tests; MRI; Oxford three-part knee
1960s Patenting/development of: continuously variable transmission; cephalosporin antibiotics; pyrethrin insecticides
1950s Patenting of interferon
1948 National Research Development Corporation founded by UK government to commercialise publicly funded research.


  • cell

    The BTG journey

  • Leadership

    Our Leadership Team has a broad range of experience and is responsible for managing the business on a day‑to‑day basis. Our Board of Directors come from a wide range of backgrounds enabling us to access a broad knowledge base.

    Leadership Team Board of Directors
  • Partnering

    BTG welcomes new opportunities for licensing and acquisition. Our Business Development strategy is focused on opportunities that complement our current product portfolio, capabilities and overall growth strategy with a focus on late-stage development and marketed products.

    Read more